Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).
Researchers are assessing the combination of BNT326 and BNT327 in people with advanced lung cancer that has spread. The people in this study have non-small cell lung cancer (NSCLC) that came back or keeps growing after treatment.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Researchers are comparing three different treatments for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment. If you join this study, you will be randomly assigned to get one of these treatments:
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
Researchers want to see how well ulixertinib works in people with histiocytic neoplasms. Histiocytic neoplasms are rare diseases in which too many white blood cells called histiocytes build up in tissues and organs. This can cause damage to tissue or tumor(s) to form. The tumor(s) may be benign (not cancer) or malignant (cancer). There are different types of histiocytic neoplasms, including:
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
The purpose of this study is to evaluate the effectiveness of treating patients with recurrent and newly diagnosed glioblastoma using new therapies that are thought to be effective for treating brain cancer. The new therapies available as part of this clinical trial include regorafenib, VAL-083, and paxalisib.
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.
